UNSPSC 51312201: Azatadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 94Z39NID6C, chemically known as 6,11-dihydro-11-(1-methyl-4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine but generally known as azatadine, which bears US NIH Compound Identifier 19861. Azatadine most often comes in base, dimaleate, and maleate forms.

UNSPSC 51312201 Azatadine, a Commodity code, nominally refers to a specific antihistamine drug, but recent state and local procurement activity under this code spans a broader range of pharmaceutical procurement and supply chain activities. State and local buying here includes direct purchase of emergency-response medications (naloxone), establishment of multi-state cooperative pharmaceutical supply agreements covering generic and over-the-counter products, and exploration of direct-to-manufacturer prescription fulfillment models. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both single-jurisdiction emergency-response procurement and regional or statewide pharmaceutical supply consolidation efforts.

Geographic activity centers on Florida and the upper Midwest (Minnesota, Oregon through MMCAP participation) and Texas. Representative recent opportunities include Seminole County's IFB60459723LAS, an IFB posted June 30, 2026, with a July 26, 2023 response date, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems for quarterly delivery to the Seminole County Community Health Building with a two-year initial term and one-year renewal option; Texas HHS's RFI HHS0017013, posted April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and Minnesota's MMCAP multi-state cooperative RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with a March 26, 2026 response deadline, requiring manufacturer participation through authorized wholesalers with contract effectiveness July 1, 2026. The code sees intermittent activity driven by specific agency needs rather than continuous baseline procurement.